IDGGW (Interpace Biosciences) Tax Provision : $-0.02 Mil (TTM As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Interpace Biosciences Tax Provision?

Interpace Biosciences's tax provision for the three months ended in Sep. 2024 was $-0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.02 Mil.

Interpace Biosciences Tax Provision Historical Data

The historical data trend for Interpace Biosciences's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Interpace Biosciences Tax Provision Chart

Interpace Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

0.03

-0.05

0.71

-0.03

-0.02

Interpace Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Tax Provision	Get a 7-Day Free Trial															-	-0.01	-	-	-

Interpace Biosciences Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02 Mil.

Interpace Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (OTCPK:IDGGW) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

IDXG:USA PF42:Germany

Address

2001 Route 46, Suite 310, Waterview Plaza, Parsippany, NJ, USA, 07054

Website

https://www.interpace.com

Interpace Biosciences Inc is a fully integrated commercial company. It provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first line assays principally focused on early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology.